Table 2.
Economic evaluation.
| Targeting (coverage, gender, age) | Vaccine regimensa,d (in million) | DALYs averteda,b (in million) | Vaccine costc (in US$) | ART cost savinga,b (in million US$) | |
|---|---|---|---|---|---|
| Fast Track with PrEP | 50% men & women age 15 | 5.61 | 0.07 (0–0.16) | 105 (0–236) | 486.33 |
| 50% men age 20 & women age 15 | 5.57 | 0.18 (0.1–0.26) | 272 (166–388) | 1158.21 | |
| 80% men & women age 15 | 8.69 | 0.19 (0.11–0.26) | 176(103–248) | 1181.60 | |
| 80% men age 20 & women age 15 | 8.64 | 0.19 (0.11–0.28) | 186(106–266) | 1255.39 | |
| 50% men & women age 18 | 5.55 | 0.21 (0.11–0.29) | 307 (187–437) | 1286.80 | |
| 50% men age 23 & women age 18 | 5.48 | 0.26 (0.16–0.35) | 383 (240–527) | 1592.42 | |
| 80% men & women age 18 | 8.60 | 0.29 (0.19–0.39) | 277 (193–370) | 1810.46 | |
| 80% men age 23 & women age 18 | 8.50 | 0.37 (0.27–0.45) | 354(261–444) | 2286.89 | |
| 60% men & women age 15–32 | 15.52 | 0.74 (0.65–0.82) | 361(320–401) | 4543.12 | |
| 60% men & women age 18–35 | 15.14 | 0.77 (0.69–0.85) | 385 (349–426) | 4705.41 | |
| Status Quo without PrEP | 50% men & women age 15 | 5.53 | 0.37 (0.24–0.49) | 533 (352–724) | 2176.25 |
| 50% men age 20 & women age 15 | 5.50 | 0.54 (0.41–0.67) | 786 (613–968) | 3192.02 | |
| 80% men & women age 15 | 8.57 | 0.53 (0.4–0.68) | 500 (371–617) | 3177.77 | |
| 80% men age 20 & women age 15 | 8.52 | 0.7 (0.56–0.83) | 659 (541–782) | 4158.92 | |
| 50% men & women age 18 | 5.45 | 0.41 (0.27–0.54) | 604 (394–807) | 2448.40 | |
| 50% men age 23 & women age 18 | 5.36 | 0.51 (0.36–0.66) | 763 (556–989) | 3022.80 | |
| 80% men & women age 18 | 8.45 | 0.62 (0.5–0.74) | 589 (481–689) | 3700.01 | |
| 80% men age 23 & women age 18 | 8.32 | 0.81 (0.68–0.95) | 787 (657–915) | 4833.93 | |
| 60% men & women age 15–32 | 15.15 | 1.45 (1.32–1.59) | 718 (652–795) | 8634.57 | |
| 60% men & women age 18–35 | 14.69 | 1.47 (1.33–1.6) | 749 (679–810) | 8665.38 | |
All numbers are averaged over 50 simulations, with full booster retention. 95% confidence intervals, if provided, are in parentheses.
a
Cumulative sum 2027–2047.
b
5% annual discount starting in 2018.
c
Maximum vaccine cost at a cost-effectiveness threshold of 1× GDP. This takes ART cost saving into account, it is not an additional benefit.
d
Number of primary series of five vaccinations administered.